ReCode Therapeutics

64 articles about ReCode Therapeutics

• ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis

  2/21/2024

  ReCode Therapeutics today announced that the first cohort of healthy volunteer participants have been dosed in a Phase 1 clinical study of RCT2100, an inhaled mRNA-based investigational therapy for cystic fibrosis (CF) that focuses specifically on the 10-13% of patients with nonsense mutations that do not respond to or experience side effects with, approved CFTR modulators.

• ReCode Therapeutics to Participate in February Conferences

  2/20/2024

  ReCode Therapeutics today announced that company management will participate in the upcoming February conferences.

• Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

  2/15/2024

  Intellia Therapeutics, Inc. and ReCode Therapeutics announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis.

• ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia

  1/3/2024

  ReCode Therapeutics today announced that a patient was treated with RCT1100, a novel mRNA-based therapy currently being evaluated in a Phase 1 study in patients with primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene.

• ReCode Therapeutics to Participate in November Conferences

  11/10/2023

  ReCode Therapeutics today announced that company management will participate in the upcoming November conferences.

• 

  Top Companies Hiring Research Associates Right Now

  11/9/2023

  Research associates are always in demand. Check out these top companies currently hiring RAs.
• 

  ReCode Raises $260M in Series B Financing to Advance Lead Programs

  9/20/2023

  Bringing in an additional $50 million in a Series B extension, ReCode Therapeutics’ total haul for the funding round totaled $260 million, which it will use to further its experimental mRNA therapies.

• ReCode Therapeutics Announces Closing of Extension to Series B Financing

  9/19/2023

  ReCode Therapeutics today announced the closing of an extension to its Series B financing.

• ReCode Therapeutics to Present at September Investor Conferences

  9/7/2023

  ReCode Therapeutics today announced that Company management will participate in the following upcoming investor conferences in September 2023.

• ReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs

  7/10/2023

  ReCode Therapeutics announced today the appointment of Erica Jefferson as senior vice president of corporate affairs.

• 

  ReCode, Vertex and 4DMT Seek to Help Untreated Cystic Fibrosis Patients

  6/5/2023

  Drugs that act on the CFTR protein only work in patients who produce the protein in the first place. That leaves 6% of patients hanging.

• ReCode Therapeutics to Present at Jefferies Healthcare Conference - June 2, 2023

  6/2/2023

  ReCode Therapeutics today announced that Angèle Maki, Ph.D., Senior Vice President, Business Development of ReCode Therapeutics, will present a company overview at 8:30 a.m. ET on Friday, June 9, 2023 at the Jefferies Healthcare Conference being held in New York, NY.

• 

  ReCode–a New Contestant in the mRNA Race  

  5/22/2023

  ReCode plans to use its SORT LNP genetic medicines delivery technology to treat CF and PCD patients who don’t respond to current treatments.

• ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development

  4/17/2023

  ReCode Therapeutics announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.

• ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

  3/27/2023

  ReCode Therapeutics today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat at 9:35 a.m. ET on Monday, April 3, 2023 at the virtual Guggenheim Healthcare Talks.

• ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

  3/21/2023

  ReCode Therapeutics today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a panel discussion titled “Novel LNPs Targeting Diverse Tissues” at 10:00 a.m. ET on Tuesday, March 28, 2023 at the virtual BMO Biopharma Spotlight Series.

• ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia

  3/15/2023

  ReCode Therapeutics announced today that the first healthy volunteer participants have been dosed in a Phase 1 clinical trial of RCT1100, a first-in-class, mRNA-based genetic medicine for the treatment of people with primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene.

• Recode Therapeutics Expands Leadership Team with Appointment of April Loui as Senior Vice President of Quality and CMC Regulatory Affairs

  2/1/2023

  ReCode Therapeutics announced today the appointment of April Loui, MBA, CSSBB, as senior vice president of quality and chemical, manufacturing and controls (CMC) regulatory affairs.

• ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy

  1/10/2023

  ReCode Therapeutics announced today that it will receive a strategic investment from the Cystic Fibrosis Foundation (CF Foundation) to develop ReCode’s inhaled mRNA-based therapeutic for people with cystic fibrosis (CF), including those with genotypes that do not respond to approved CFTR modulators.

• ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform

  1/9/2023

  ReCode Therapeutics announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio).